Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection

MT Newswires Live04-16

Gan & Lee Pharmaceuticals (SHA:603087) received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.

The drug will be tested for the treatment of neovascular (wet) age-related macular degeneration in adults.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment